Search PubMed⌕ Search

Biomedical subjects

H Ditschuneit

Publications and source records attributed to H Ditschuneit.

At least 199 records · Page 11Linked to original sources
PubMed1980

Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.

In the present study we examined the effect of different lipid lowering drugs on lipids and lipoproteins in hyperlipoproteinemia type IIa. We have treated over 24 weeks 10 patients with 900 mg beta-pyridylcarbinol daily, 11 patients with 3 g of xantinolnicotinate, 4 patients with 600 mg bezafibrate daily and 10 patients with a combination of 2.4 g inositolnicotinate and 1.5 g clofibrate daily. One patient with familial hypercholesterolemia (untreated total cholesterol 800 mg%) received a combined drug treatment during 5 years. Total cholesterol decreased to 200 mg%, mainly due to decreases in LDL-cholesterol. However in HDL significant decreases of about 50% could be observed. Treatment with the four different drugs showed significant decrements in low density lipoproteins (LDL) whereas an increase of protective high density lipoproteins could not be observed.

Adolescent↗
PubMed1980

Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.

In this study we examined the influence of different lipid lowering drugs (xantinolnicotinate (Xn), bezafibrate (Bf) and a combination of inositolnicotinate and clofibrate (In-Cl)) on the lipid and lipoprotein concentration in 61 hyperlipidemics of the types IIb, IV and V. Treatment with the 3 drugs showed a significant LDL-cholesterol decrease in type IIb and a LDL-cholesterol increase in the types IV and V. Concerning protective HDL lipoproteins an increase of HDL-cholesterol could be observed in all three types only by treatment with xantinolnicotinate and bezafibrate. Concomitantly in type V a type conversion to type IV could be observed under drug treatment regarding the chemical composition of the lipoprotein fractions VLDL, LDL and HDL.

Anticholesteremic Agents↗
PubMed1978

[Mayo diet].

Explore the source record for details and available documents.

Age Factors↗
PubMed1978

[The meso-caval shunt--a future standard operation?].

As a result of several retrospective and prospective studies, there have been remarkable changes in surgery for portal hypertension, namely the limitation of surgical interventions to an asymptomatic time interval (without bleeding), and the preference for distal shunt operations, aiming at a lasting reduction of the portal hypertension with minimal reduction of portal liver perfusion. These requirements are best met by the mesocaval (H-) shunt, using a vascular prosthesis with sufficient wall stability and a negatively charged inner surface, such as, for example, the expanded PTFE graft (Gore-TEX). In contrast to several types of splenorenal shunt, the H-shunt in mesocaval position is characterized by the following advantages: (a) minimal operative stress, even in high-risk patients, (b) technical ease of use, (c) reduced operative mortality, especially for interval operations, (d) minimal risk of recurrent bleeding and encephalopathy. From this preliminary report it may be expected that the technique of mesocaval expanded PTFE shunt here presented is likely to become the method of choice in both elective and emergency interventions.

Humans↗
PubMed1977

[Total fasting].

Explore the source record for details and available documents.

Acid-Base Equilibrium↗
PubMed1976

[Dietary problems in the management of type I hyperlipoproteinemia (author's transl)].

The therapeutic effect of different diets varying in long chain and medium chain triglycerides, carbohydrate, and protein was tested in two siblings with type I hyperlipoproteinemia. Despite administration of an extremely fat reduced diet ( less than 5 g daily), a normalization of plasma TG could not be obtained because-as a consequence of its high carbohydrate and/or its MCT content-it resulted in a considerable increase in pre-beta-lipoproteins. As life long dietary therapy has to be maintained, the risks of a normal therapy has to be maintained, the risks of a normal fat containing diet (mainly bouts of pancreatitis) and those of a carbohydrate and MCT rich diet (premature atherosclerosis) are to be carefully considered. On the basis of our data we therefore suggest the following dietary regimen: 1. Reduced intake of long chain triglycerides (less than 30 gms per day), but with sufficient amounts of essential fatty acids (4-6 gms linoleate daily). 2. The carbohydrates should not exceed 50% of total calories and ought to consist mainly of starch. 3. The caloric deficit thus generated should be balanced by a high protein intake. This is faciliated by applying a specially protein-enriched food. 4. Medium chanin triglycerides may be necessary when adherence to the protein-rich diet turns out to be bad.

Adult↗
PubMed1976

Treatment of type II hyperlipoproteinemia with d-thyroxine.

The effectiveness of a new, almost l-thyroxine free preparation of d-thyroxine (Dynothel) was tested in 15 patients with Type IIa and 4 patients with Type IIb hyperlipoproteinemia. Eleven patients with Type IIa and 3 with Type IIb were responsive to treatment and showed an average 26% decrease in plasma TC. This decrement in plasma TC was mirrored in a significant reduction of LDL cholesterol in Type IIa and IIb. While VLDL cholesterol slightly decrease in Type IIb, it remained the same in Type IIa and so did the HDL cholesterol in both types. As neither VLDL nor LDL or HDL triglyceride levels changed very much in either type, the total plasma triglycerides remained the same. The plasma phospholipids were higher in Type IIa and lower in Type IIb on therapy. Thus, Dynothel seems to be a potent d-thyroxine preparation for lowering plasma cholesterol, this decrease being brought about by reduction of LDL cholesterol levels. The effect of the drug on plasma TG and PL is less certain.

Adolescent↗